Trials / Completed
CompletedNCT06893081
A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)
An Open-label, Phase 1 Study to Characterize the Effects of a Strong CYP3A4 Inducer on the Pharmacokinetics of MK-8527 in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time when MK-8527 is given alone and with the medication CBZ.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8527 | Oral Tablet |
| DRUG | CBZ | Oral Extended-release Capsule |
Timeline
- Start date
- 2025-04-28
- Primary completion
- 2025-06-19
- Completion
- 2025-07-17
- First posted
- 2025-03-25
- Last updated
- 2025-07-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06893081. Inclusion in this directory is not an endorsement.